Eisai Exits Dermatology Through Roivant Deal
This article was originally published in PharmAsia News
Executive Summary
Eisai has followed in the footsteps of Japanese peer Astellas by divesting assets in the dermatology area, this time through a deal with Roivant for a clinical stage atopic dermatitis therapy that it sees as no longer fitting into its strategic priorities.